Pregnancy & Lactation : הריון/הנקה

4.6   Fertility, pregnancy and lactation
Pregnancy
Mometasone Furoate:
There are no or limited amount of data from the use of mometasone furoate in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3).
Olopatadine:
There are no or limited amount of data from the use of intranasal olopatadine in pregnant women.
Studies in animals have shown reproductive toxicity following systemic administration (see section 5.3).
Ryaltris should not be used in pregnancy unless the potential benefit to the mother justifies any potential risk to the mother, foetus or infant. Infants born of mothers who received corticosteroids during pregnancy should be observed carefully for hypoadrenalism.


Breast-feeding
Mometasone Furoate:
It is unknown whether mometasone furoate is excreted in human milk
Olopatadine:
Available data in animals have shown excretion of olopatadine in milk following oral administration (for details see section 5.3). A risk to the newborn/infants cannot be excluded.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Ryaltris therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.
Fertility
There are only limited data with regard to fertility.
There are no clinical data concerning the effect of mometasone furoate on fertility.
Animal studies have shown reproductive toxicity, but no effects on fertility.
There are no clinical data concerning the effect of olopatadine on fertility